Table 3 Number of patient blood draws per treatment modality and visit
Treatment Groupa | Baseline | 6Â Month | 12Â Month | Subtotal |
|---|---|---|---|---|
Radiation + Hormonal | 59 (29.5%) | 52 | 52 | 163 |
Hormonal | 31 (15.5%) | 25 | 26 | 82 |
Radiation + Hormonal + Chemotherapy | 25 (12.5%) | 23 | 22 | 70 |
Surgery Only | 24 (12.0%) | 15 | 10 | 49 |
Hormonal + Chemotherapy | 15 (7.5%) | 12 | 13 | 40 |
Radiation | 13 (6.5%) | 8 | 8 | 29 |
Radiation + Chemotherapy | 11 (5.5%) | 11 | 11 | 33 |
Radiation + Hormonal + Chemotherapy + Trastuzumab | 8 (4.0%) | 8 | 8 | 24 |
Chemotherapy | 5 (2.5%) | 4 | 5 | 14 |
Hormonal + Chemotherapy + Trastuzumab | 5 (2.5%) | 5 | 5 | 15 |
Radiation + Chemotherapy + Trastuzumab | 3 (1.5%) | 2 | 2 | 7 |
Radiation + Hormonal + Trastuzumab | 1 (0.5%) | 1 | 1 | 3 |
Total number of samples | 200 (100%) | 166 | 163 | 529 |